Form Type:  SC 13G
Filing Date:  7/11/2022 
CIK:  0001699382 
Address:  8 CLARKE DRIVE 
City, State, Zip:  CRANBURY, New Jersey 08512 
Telephone:  (609) 642-6664 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.17 (1.69%)  
Trade Time: 
Nov 25  
Market Cap: 
Trade PMVP now with 

© 2022  
Description of Business
We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the "guardian of the genome," and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function.
Register and access this filing in: